Skip to main content
Premium Trial:

Request an Annual Quote

Roger Stoll, Norman Hardman, Jason Stein, John Gill, Steven Nichtberger, Reid Dulberger, Walt Good, Matt Michels, David Welsh, Jean-Francois Gimonet, Carlo Montagner, Rick Click, Lisa Guttman, B. Joseph White, Yoshihiko Hatanaka, Paul Willems, Yonnie Butl

Chelsea Therapeutics Adds Two Independent Directors to Its Board; Founding Director Resigns
Roger Stoll and Norman Hardman have been appointed to the board of directors of Chelsea Therapeutics International, a Charlotte, NC, biopharmaceutical company. Their appointments increase the number of the board’s independent directors to six and the board's total membership to seven.
Stoll is the chairman, president and CEO of Cortex Pharmaceuticals. Before joining Cortex, he was the executive vice president of Fresenius Medical Care-North America, where he oversaw both the dialysis products and laboratory services groups, responsible for combined sales of approximately $900 million.
From 1991 to 1998, Stoll was CEO of Ohmeda, and served on the board of directors of its corporate parent, UK-based BOC Group. Prior to that, Dr. Stoll held several positions, including president of the consumer health care group of Miles; executive vice president and general manager of the worldwide diagnostics business group at Bayer; and director of clinical pharmacology, and president of the American critical care division for American Hospital Supply, now Baxter International. He began his career at Upjohn, where he conducted human pharmacokinetic and drug metabolism clinical trials in all phases of drug development.
Stoll received his bachelor's degree in pharmacy from Ferris State University and a PhD in biopharmaceutics from the University of Connecticut. He performed postdoctoral studies in pharmacokinetics and drug metabolism at the University of Michigan.
Hardman is president and CEO of Oxalis Partners, a strategic consultant to US and EU biotechnology companies and VC venture funds, as well as an honorary professor at the University of Aberdeen, where he serves as vice president and treasurer of the University of Aberdeen Development Trust, and as an advisor to university management.
Over the last 10 years, Hardman has held senior management roles in several companies, including as president and CEO of Amicus Therapeutics, CEO of Medical Research Council Technology, senior vice president of technology for Enzon, COO at Onyx Pharmaceuticals, and president and COO at GeneMedicine. Earlier, he served as head of R&D at Ciba-Geigy, and played a central role in integrating the global R&D organization during the merger of Ciba-Geigy and Sandoz to form Novartis AG, becoming head of UK R&D operations in the merged entity in 1996.
Hardman graduated with a BSci in chemistry from the University of London, and obtained his PhD in biochemistry from the University of Manchester. His postdoctoral training included two years as medical research council fellow and a fellowship at Harvard Medical School.
Chelsea also announced the resignation of board member Jason Stein, a director since the company’s inception in 2004.

BioAdvance Appoints CEOs of Tetralogic, Tengion to Board of Directors
John Gill and Steven Nichtberger have been named to the board of directors of BioAdvance, the Philadelphia-based biotechnology greenhouse serving Southeastern Pennsylvania.
Gill is co-founder, president and CEO of Tetralogic Pharmaceuticals, a Malvern, Pa.-based developer of cancer drugs. Previously he held senior management positions in operations and finance with SmithKline Beecham and 3 Dimensional Pharmaceuticals. He also served as a founding member and partner in SR One, Limited, SmithKline Beecham's life sciences venture capital fund.
Nichtberger is president and CEO of Tengion, the suburban Philadelphia firm focused on regenerative medicine. Nichtberger is a former senior executive at Merck, where he was responsible for leadership of global marketing and new product planning, and was a core participant in many corporate licensing, divestiture, and product acquisition deals. Nichtberger is a board certified internist and cardiologist.
Established in 2002 with $33.8 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies, BioAdvance has invested more than $11.5 million in 21 early stage life sciences companies and nine academic projects.

EVP of Ohio’s Youngstown/Warren Regional Chamber Joins MemphisED Administration
Reid Dulberger, executive vice president for Ohio’s Youngstown/Warren Regional Chamber, has been named vice president of the Memphis, Tenn., Regional Chamber’s MemphisED Administration, a five-year, $63 million community economic development program, the Tribune Chronicle of Warren, Ohio, reported.
‘‘Memphis and Shelby County have significant investment in biotechnology that they intend to greatly expand. They have other technology-related initiatives. They’ve launched Ö, a venture capital firm to invest in small companies. I’ll be involved in all of those,” Dulberger told the newspaper.
Walt Good, the Youngstown/Warren chamber’s economic development director, will succeed Dulberger on an interim basis. Next week, the chamber will launch a national executive search for a permanent successor.
During his 17 years with the chamber, Dulberger and his staff carried out 335 successful business assistance projects resulting in the creation of almost 15,000 jobs, more than 13,000 retained jobs, $1.3 billion of new investment, and more than $270 million of state and federal funding for local infrastructure projects, according to the chamber.
Dulberger has master’s degrees from Carnegie Mellon and Georgetown universities, and is the Valley’s only Certified Economic Developer, the chamber said.

Arizona’s Oro Valley Hires Interim Economic Development Director
Matt Michels has been named interim economic development coordinator for Arizona’s town of Oro Valley, at an annual salary of $74,859, effective Feb. 4. He temporarily succeeds David Welsh, who left the position for a job with the economic development group Tucson Regional Economic Opportunities, The Explorer of Tuscon, Ariz., reported.

Michels told the newspaper he will “work with business retention, business attraction, and help the town to implement its community economic development strategy” — a strategy focused on biotech, given the construction in progress of a new research facility for Sanofi-Aventis and the pending acquisition by Roche Pharmaceuticals of Ventana Medical Systems, headquartered in Tucson’s Innovation Park.

Among his priorities is completing the Rancho Vistoso Planned Area Development amendment, intended to promote more life sciences development at Innovation Park. “I look forward to working with the developers to see the emergence of a strong biotechnology corridor,” Michels said.

Michels began working for Oro Valley in May 2006, and most recently had been a senior planner. Previously he worked for Mohave County, Ariz. Michels has a master’s degree in urban and regional planning from Portland State University in Oregon.


Abraxis BioScience Names Members of Global Leadership Team
Abraxis BioScience, a Los Angeles biotechnology company, has announced the appointments of four professionals to newly-created positions within its global leadership team:
  • Jean-Francois Gimonet has joined Abraxis as vice president, European operations;
  • Carlo Montagner has been named president of oncology, pan-Asia;
  • Rick Click has been appointed as global information technology/chief information officer; and
  • Lisa Guttman has joined as vice president of global clinical operations.
Gimonet will be responsible for building the company’s sales and marketing infrastructure in Europe, following the European Commission’s recent marketing approval of Abraxane, a therapy for treating metastatic breast cancer. Preparations are underway to launch ABRAXANE across Europe in mid-2008.
Before joining Abraxis, Gimonet was a senior executive at Baxter SAS for six years, last serving as global medico-marketing director. Previously, he was country manager France– (and) deputy chairman, ASTA Medica Oncology, a worldwide producer of oncology products, prior to its acquisition by Baxter. Gimonet also held several hospital research positions in oncology, and completed a 10-year academic career at the Université Paris – Val-de-Marne (Paris XII), where he earned his MD degree.
Montagner will have responsibility for establishing Abraxis in the Asia-Pacific region after establishing the marketing organization for Abraxane in the US. He joined Abraxis in 2006 after the company was formed through the merger of American Pharmaceutical Partners, and American BioScience. Previously he served as executive vice president and global business unit head of oncology for Schering. Montagner earned a MSci degree in psychology from Australia’s Royal Melbourne Institute of Technology and a BSci degree in behavioral sciences from La Trobe University, also in Australia.
Click will head the company’s international IT department and its related functions, servicing all of the company’s offices and operational facilities. Previously, he was chief information officer at Molina Healthcare and has held senior positions at eBay’s PayPal unit, American Outsourcing Group, Goodman Global Holdings, Honeywell International and Zenith Electronics. He is a graduate of California Coast University and earned an MBA degree and a professional masters degree from Harvard Graduate School of Business.
Guttman joined Abraxis after serving for more than seven years at Amgen, most recently as director of development operations. Previously, she worked at Eli Lilly for 10 years in increasingly senior positions in clinical research. Guttman holds an honors BSci degree in molecular biology and an MBA degree from McMaster University in Hamilton, Ontario, Canada.

iBIO Announces Keynote Speakers for its Industry Expo & Marketplace
The Illinois Biotechnology Industry Organization has announced three keynote speakers for its 2008 iBIO Industry Expo and Marketplace, a daylong conference to be held Feb. 20 at the Hyatt Regency hotel in downtown Chicago:
  • B. Joseph White, president of the University of Illinois,
  • Yoshihiko Hatanaka, president and CEO of Astellas US, the American subsidiary of Tokyo-based Astellas Pharma, and
  • Paul Willems, technology vice president for energy biosciences with BP Group
White has served as President of the University of Illinois since January 2005. Previously he spent nearly three decades affiliated with the University of Michigan at Ann Arbor, where he received his doctorate in business administration in 1975. White earned his bachelor’s degree, magna cum laude, in international economics from the Georgetown University School of Foreign Service in 1969 and an MBA, with distinction, from Harvard University in 1971.
Hatanaka joined Astellas in 1980 as a marketing analyst in the pharmaceutical division, in Osaka, Japan, and then spent several years as a medical sales representative before advancing to associate manager of marketing planning in the Tokyo office. He was assigned to the US in 1992 as director of marketing planning for immunology. Hatanaka has a bachelor's degree in economics from the Hitotsubashi University, and serves on the boards of the Pharmaceutical and Research Manufacturers of America, the New York Pharma Forum, and Japanese Chamber of Commerce Chicago.
Willems is responsible for integrating biotechnology into BP’s business activity. He is also associate director for the Energy Biosciences Institute, a 10-year research collaboration between the University of California at Berkeley, the Lawrence Berkeley National Lab, the University of Illinois in Urbana-Champaign and BP. Willems previously served as business technology manager for BP’s global purified terephthalic acid business, and as technology vice president for acetyls and aromatics. Willems earned a PhD in Chemical Engineering from the University of Ghent in Belgium in 1986.

NC Biotech Center Names Veteran Consultant New Business Development Director
Yonnie Butler has been named business development director in the business and technology development unit of the state-funded North Carolina Biotechnology Center. Butler succeeds Steven Casey, who has been promoted by the biotech center to vice president of its statewide operations.
Butler previously served as business development executive and managing consultant in charge of several large North American pharmaceutical accounts for Tunnell Consulting, headquartered in the Philadelphia area. He has also held positions for Roche, LabCorp, Magellan Laboratories, Cardinal Health, and PharmaDirections.
Butler received his BSci degree in biology from East Carolina University and holds an MBA from Elon University. He has served as a business plan reviewer for Duke University and the biotechnology center; mentored MBA students from Duke University, Wake Forest University, and North Carolina State University; lectured at the East Carolina University School of Business; and assisted several academic programs that foster entrepreneurship. In addition, Butler has served as an adjunct instructor for several community colleges in North Carolina, and provided training to several companies through the NC BioNetwork initiative.

Carlsbad, Calif., Biosample Products Maker Names New VP of Sales and Marketing

Mark Ostrowski has been named vice president of sales and marketing for GenVault, a Carlsbad, Calif., provider of biosample workflow, transport, and storage products. Ostrowski will oversee GenVault's domestic and international sales and marketing efforts.
Ostrowski spent more than 10 years at Myriad Genetics Laboratories, where he was most recently director of sales operations. At Myriad, Ostrowski planned and directed a 200-person sales organization that generated an average annual compound growth rate of 54% over the last decade. 
Prior to Myriad, Ostrowski commercialized pathology and oncology diagnostics to clinicians and healthcare organizations for Dianon Systems, since acquired by Laboratory Corporation of America. Ostrowski holds a BSci in biology from Yale University.

CB Richard Ellis Hires Senior Communications Pro from Rival Brokerage
Philip Russo has joined CB Richard Ellis assenior director of communications for New York City, with responsibility for raising the real estate firm’s profile there. Russo comes to CBRE from rival Cushman & Wakefield, where he was senior managing director of media and corporate affairs.
At C&W, Russo coordinated global internal and external messaging, media relations, speechwriting and produced a host of comprehensive corporate communications on behalf of the firm’s executive leadership. He was previously managing director of C&W’s media relations unit, and prior to that served as director of New York metropolitan area public relations for the firm.
Russo also served as director of the Office of Special Projects & Publications in the public affairs division of New York City’s former Board of Education. He also served as the assistant commissioner for public affairs for the New York City Department of Housing Preservation and Development.
Russo is a graduate of Fordham University and lives in New York City. His appointment allows CBRE’s senior director of corporate communications, Robert McGrath, to focus exclusively on spearheading the firm’s national media and public relations efforts.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.